KMT2A and leukemia: LEDGF/p75 knockout was found to inhibit disease progression in MLL murine models, suggesting a critical dependence of MLL leukemogenesis on the transcriptional and pro-survival functions of this protein, implicating it as a potential therapeutic target for leukemias [134].